Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Reblozyl Faces Price Cut after Cost-Effectiveness Assessment
September 11, 2025
- Generics to Be Exempt from Tariffs under US-Japan Deal: Govt Officials
September 10, 2025
- Label Revisions Ordered for Antihypertensives, Adalimumab, I/O Meds, and More
September 10, 2025
- Japan Panel Approves 5 COVID Vaccines for NIP Use from October
September 9, 2025
- MHLW Seeks to Raise Quality of Prefectural Generic GMP Inspections
September 8, 2025
- MHLW Panel Backs Draft ARI Prevention Guidelines, Due Out November
September 5, 2025
- Japan Kicks Off Debate on Medical Data Use Framework, Eyes 2027 Legislation
September 4, 2025
- MHLW Seeks Sponsor for Drug Loss Product Trifarotene
September 4, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Generics Surge in FY2024 on New Out-of-Pocket Rule for Long-listed Drugs
September 3, 2025
- Pharma Groups Press Pricing Reform at First Public-Private WG Meeting
September 2, 2025
- Japan Panel Clears Izervay, Nexletol for Approval; Eylea Biosimilars Edge Ahead Too
September 1, 2025
- METI Proposes “Bold Investment” Tax Breaks in FY2026 Request
September 1, 2025
- Japan Panel Green Lights Nonprescription Switch of Morning-After Pill
September 1, 2025
- MHLW Orders Label Revision for Elevidys to Add Acute Hepatic Failure
September 1, 2025
- Japan Doles Out Orphan Tags to Ultragenyx’s GTX-102 and Lots More
September 1, 2025
- Japan Expects COVID Vaccine Supply of 9 Million Doses in 2025-26
September 1, 2025
- Japan Govt to Spearhead Development of Ultra-Orphan and Infectious Disease Drugs: FY2026 MHLW Budget Request
August 29, 2025
- Japan Moves Toward OTC Morning-After Pill Sales Without Age Limit or Parental Consent
August 29, 2025
ページ
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Let’s ditch the stuffy jargon and talk about AI in HR like real humans.One of the biggest myths floating around is that AI is coming to steal our jobs. Newsflash: that’s not happening. Sure, AI can handle the boring stuff…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…